Sermorelin: Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 11 sources cited
Overview
Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of the native 44-amino acid GHRH sequence. It is the shortest fragment of GHRH that retains full biological activity at the pituitary. Sermorelin was FDA-approved for the diagnosis and treatment of growth hormone deficiency in children, and both Geref products are now listed as discontinued and has become one of the most widely used growth hormone secretagogues in anti-aging and peptide therapy. Unlike exogenous GH, sermorelin stimulates natural pulsatile GH release, preserving the body's feedback mechanisms.
Mechanism of Action
Sermorelin (GRF 1-29 NH2) binds to the GHRH receptor (GHRH-R) on somatotroph cells in the anterior pituitary gland. The GHRH-R is a G-protein coupled receptor that activates adenylyl cyclase via Gsα, increasing intracellular cAMP levels. This triggers protein kinase A (PKA) signaling, which opens voltage-gated calcium channels and promotes the transcription and secretion of stored growth hormone. Critically, sermorelin works within the physiological feedback system — it can only stimulate GH release when somatostatin tone is low (typically during deep sleep and after exercise), preserving the natural pulsatile pattern of GH secretion. This is fundamentally different from exogenous GH injection, which provides a single supraphysiological spike and suppresses endogenous production via IGF-1 negative feedback. In animals, chronic GHRH or secretagogue treatment increases the secretory granule density of somatotrophs, and GHRH-overexpressing mice develop somatotroph hyperplasia; a gain in pituitary capacity has not been shown in people. This is a key advantage for aging patients whose GH decline is partly due to reduced pituitary capacity. Additionally, GHRH activates sleep-regulating neurons of the preoptic hypothalamus in rats, and in people repeated GHRH injections increased non-REM sleep during recovery from sleep deprivation, although systemic GHRH impaired sleep in healthy young women.
Sermorelin Benefits: What the Research Shows
- Reviews of the sermorelin literature describe GRF 1-29 as the shortest synthetic GHRH peptide with full biological activity, stimulating GH secretion from the anterior pituitary in children and adults
- Vittone et al. (1997, Metabolism) found that 6 weeks of nightly GHRH(1-29) in 11 elderly men raised nocturnal GH release and improved two measures of muscle strength, with no change in IGF-1 or body composition
- Sermorelin was approved by FDA as a provocative test for GH deficiency (Geref, 1990) and later for treating short stature in children with idiopathic GH deficiency
- Repeated GHRH injections increased non-REM sleep during recovery from sleep deprivation in 48 healthy adults (Schüssler et al., 2006), while systemic GHRH impaired sleep in healthy young women
- A 16-week trial of nightly GHRH(1-29) in men and women aged 55 to 71 raised 12-hour nocturnal GH levels and IGF-1 (Khorram et al., 1997, Journal of Clinical Endocrinology and Metabolism)
- Khorram et al. (1997, Journal of Clinical Endocrinology and Metabolism) reported that 16 weeks of a GHRH(1-29) analog increased skin thickness in both sexes and lean body mass in men only
- Research demonstrates that combined GHRH + GHRP administration produces synergistic GH release, well above what either agent produces alone
- Published sermorelin trials ran from weeks to about a year, which is too short to say anything about cancer risk or long-term pituitary function
Sermorelin Dosage
- Standard anti-aging dose: 200–300 mcg subcutaneous injection at bedtime, 5–6 nights per week
- Loading phase: some protocols use 300 mcg nightly for the first 3 months, then reduce to 200 mcg for maintenance
- Clinical protocols: 100–300 mcg daily or every other day
- Always inject on an empty stomach — food, particularly fats and carbohydrates, suppresses the GH response
- Bedtime dosing is critical to synergize with the natural nocturnal GH pulse during deep sleep
- Avoid eating within 90 minutes of injection; avoid high-glycemic foods within 2 hours
- Cycle: 3–6 months on, 1 month off, though many clinics prescribe continuous use
- Often combined with GHRP (ipamorelin or GHRP-2) for synergistic GH release — the combination can produce 3–5x greater GH release than either alone
- First 1–3 months may show modest results; full effects develop over 3–6 months as pituitary responsiveness improves
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
Sermorelin Side Effects & Safety
Known Side Effects
- Injection site reactions (redness, swelling, pain) are the most commonly reported side effect
- Transient flushing and warmth immediately after injection (due to vasodilatory effects)
- Headache, particularly in the first 1–2 weeks of use
- Dizziness or lightheadedness shortly after injection
- Water retention and joint stiffness — signs of effective GH elevation, usually mild
- Vivid dreams and altered sleep architecture (often perceived as a benefit)
- Rare: transient hyperglycemia at high doses, as GH is a counter-regulatory hormone
Safety Profile
Sermorelin has one of the strongest safety profiles among GH-stimulating peptides, backed by its history as an FDA-approved pharmaceutical (Geref). Because it works through the natural GHRH receptor and preserves pulsatile GH release, it avoids the supraphysiological GH spikes and IGF-1 elevations associated with exogenous GH injection. The risk of GH-related side effects (carpal tunnel, insulin resistance, edema) is substantially lower. Sermorelin does not suppress endogenous GH production, and the idea that it enhances pituitary capacity over time rests on animal data. It is contraindicated in patients with active malignancy (as GH may promote tumor growth), untreated hypothyroidism, and hypersensitivity to GHRH analogs. Trials in children and older adults reported mainly injection site pain, facial flushing and, in one study, transient hyperlipidemia. Nocturnal cortisol fell after GHRH in a controlled sleep study, and effects on the thyroid and sex hormone axes are not established. Elderly patients tolerate it well. Drug interactions are minimal, though glucocorticoids can blunt the GH response.
What to Expect
Week 1–2: Users commonly report deeper sleep and vivid dreams, though sleep quality did not change in the one controlled sermorelin-analog trial that measured it. Some users notice a subtle sense of well-being. Week 3–6: Sleep improvements consolidate. Recovery from exercise improves noticeably. Skin may begin to appear more hydrated. Mild water retention is possible. Week 6–12: Lean body composition changes become measurable. Fat loss (particularly visceral) and modest lean mass gains. Improved exercise recovery is clearly apparent. Nail and hair growth may accelerate. Week 12–24: Full effects manifest — improved body composition, skin elasticity, energy levels, exercise capacity, and cognitive function. IGF-1 levels typically normalize or reach upper-normal range. Many users report the most dramatic improvements during months 3–6. Week 24+: Sustained benefits with continued use. The pituitary becomes more responsive over time, meaning some users can reduce their dose while maintaining effects.
Common Stacks
Ipamorelin
Ipamorelin (a GHRP) acts on the ghrelin receptor while sermorelin acts on GHRH-R — together they produce synergistic GH release 3–5x greater than either alone, the gold standard peptide GH protocol
CJC-1295 (No DAC)
CJC-1295 is a longer-acting GHRH analog that can be combined with sermorelin for sustained GH elevation throughout the day
Tesamorelin
Both are GHRH analogs but tesamorelin has a trans-3-hexenoic acid modification giving different receptor kinetics; some practitioners alternate between them
Storage & Handling
Store lyophilized sermorelin at 2–8°C, protected from light. For long-term storage (>6 months), -20°C is recommended. Reconstitute with bacteriostatic water (0.9% benzyl alcohol); direct water down the vial wall and swirl gently — do not shake. Reconstituted solution: store at 2–8°C and use within 28 days. The peptide is sensitive to heat degradation; never leave at room temperature for extended periods. Discard if solution appears cloudy or contains particulates.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- Drugs@FDA: GEREF (sermorelin acetate) injection, NDA 020443. U.S. Food and Drug Administration. 1997.
- Drugs@FDA: GEREF (sermorelin acetate), NDA 019863. U.S. Food and Drug Administration. 1990.
- FDA Briefing Document, Pharmacy Compounding Advisory Committee: evaluation of ipamorelin-related bulk drug substances. U.S. Food and Drug Administration. 2024.
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999.
- Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997.
- Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997.
- Schüssler P, Yassouridis A, Uhr M, et al. Growth hormone-releasing hormone and corticotropin-releasing hormone enhance non-rapid-eye-movement sleep after sleep deprivation. Am J Physiol Endocrinol Metab. 2006.
- Mathias S, Held K, Ising M, et al. Systemic growth hormone-releasing hormone (GHRH) impairs sleep in healthy young women. Psychoneuroendocrinology. 2007.
- Peterfi Z, McGinty D, Sarai E, et al. Growth hormone-releasing hormone activates sleep regulatory neurons of the rat preoptic hypothalamus. Am J Physiol Regul Integr Comp Physiol. 2010.
- Jiménez-Reina L, Cañete R, de la Torre MJ, et al. Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Histol Histopathol. 2002.
- Veldhuis JD, Bowers CY. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. Am J Physiol Endocrinol Metab. 2009.
Related Peptides
Track Sermorelin in Your Protocol
Log your Sermorelin doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free